Korro Bio, Inc.

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio granted non-statutory stock options to purchase 4,000 aggregate shares to two newly hired employees as employment inducements. The options carry a $8.88 exercise price equal to the October 14, 2026 Nasdaq closing price, with a ten-year term and four-year vesting including a one-year cliff. The grants were approved by the independent Compensation Committee under the 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4); this is routine boilerplate with no material financial impact.

•9d ago

Korro to Participate in Upcoming Investor Conferences

Korro Bio announced that CEO Ram Aiyar will participate in the Citi 2026 Biopharma Back to School Summit on September 9 and the 2026 Cantor Global Healthcare Conference on September 10. The fireside chats will be moderated by Yigal Nochomovitz of Citi and Steve Seedhouse of Cantor, respectively. Korro leverages its OPERA platform to develop RNA-editing therapies for rare and prevalent diseases.

•1mo ago

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio granted a non-statutory stock option to a newly hired employee as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The option covers 600 shares at an exercise price of $13.35 per share, which was the closing price on the grant date of August 12, 2026. The award has a ten-year term and vests over four years, with 25% vesting on the first anniversary and the remainder in monthly installments.

•2mo ago

KRRO: 8-K · material agreement

Korro Bio entered into a warrant exchange agreement with Venrock Healthcare Capital Partners on August 5, 2026, surrendering 1,000,000 shares for pre-funded warrants to purchase an equal number of shares. The company reported a net loss of $18.9 million for the second quarter of 2026, with cash and equivalents increasing to $137.9 million. The filing also includes financial results for the quarter ended June 30, 2026, and updates on the company's clinical pipeline.

SEC 8-K•2mo ago

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio granted non-statutory stock options to seven newly hired employees as an inducement material to their acceptance of employment with the company. The grants cover an aggregate of 23,000 shares of common stock, split into two groups with exercise prices of $10.59 and $14.72 per share respectively, based on closing prices on the grant dates. These options vest over four years and were approved by the independent Compensation Committee under Korro’s 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

•3mo ago

KRRO: 8-K · proxy statement

Korro Bio, Inc. reported the results of its 2026 annual meeting of stockholders held on June 10, 2026. Stockholders elected Nessan Bermingham and Rachel Meyers as Class I directors for three-year terms ending in 2029. The advisory vote on executive compensation passed with strong support, receiving 9,009,739 votes for and only 27,988 votes against. Additionally, stockholders ratified the selection of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026, with nearly unanimous approval.

SEC 8-K•4mo ago

Korro to Present at the 2026 Jefferies Global Healthcare Conference

Korro Bio announced that CEO Ram Aiyar will present at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 4, 2026, at 4:20 pm ET in New York. The release contains no new clinical data or business updates, serving only as a calendar notice for investors.

•4mo ago

Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Korro Bio disclosed the grant of a non-statutory stock option to one newly hired employee under Nasdaq Listing Rule 5635(c)(4). The grant covers 3,000 shares with an exercise price of $11.20, matching the closing price on the grant date of May 13, 2026. The options vest over four years, with 25% vesting on the first anniversary and the remainder in monthly installments, subject to continued service.

•5mo ago

Korro to Participate in Upcoming Investor Conferences

Korro Bio announced that members of its executive leadership team, including CEO Ram Aiyar, will participate in upcoming investor conferences. Management is scheduled to attend the HCW 4th Annual BioConnect Nasdaq Investor Conference on May 19 and the RBC Capital Markets Global Healthcare Conference on May 20. The company reiterated its intention to use its Investor Relations website and social media channels for disclosing material nonpublic information.

•5mo ago